Perioperative management of cardiac ischemia: Difference between revisions

From IDWiki
(Imported from text file)
 
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
  +
== Background ==
* Highest risk period for MI is post-op day 3
 
   
== Epidemiology ==
+
===Epidemiology===
   
* Represents 1-6% of cardiac events
+
*Represents 1-6% of cardiac events
   
== Etiology ==
+
===Etiology===
   
* Bleeding (35%)
+
*Bleeding (35%)
* Cardiac cause (44%), including MI, AV block, arrhythmias
+
*Cardiac cause (44%), including MI, AV block, arrhythmias
* Other (21%), including PE, anaphylaxis, and hypoxemia
+
*Other (21%), including PE, anaphylaxis, and hypoxemia
   
== Pathophysiology ==
+
===Pathophysiology===
   
* Thrombosis
+
*Thrombosis
* Catecholamine surges from stress state
+
*Catecholamine surges from stress state
* Obstruction
+
*Obstruction
* Infection or inflammation
+
*Infection or inflammation
* Increased demand, from tachycardia, fever, hypotension, anemia, and hypoxemia
+
*Increased demand, from tachycardia, fever, hypotension, anemia, and hypoxemia
   
== Clinical Presentation ==
+
==Clinical Manifestations==
   
 
*Highest risk period for MI is post-op day 3
* Myocardial infarction after non-cardiac surgery (MINS)
+
*[[Myocardial infarction after non-cardiac surgery]] (MINS)
* STEMI is rare
+
*[[STEMI]] is rare
   
== Diagnosis ==
+
==Diagnosis==
   
* Increased troponin with typical pattern
+
*Increased troponin with typical pattern
* Signs of ischemia, including Q waves on ECG or wall motion abnormalities on echocardiography
+
*Signs of ischemia, including Q waves on ECG or wall motion abnormalities on echocardiography
   
== Management ==
+
==Management==
   
* Treat underlying cause
+
*Treat underlying cause
* Add ASA and beta blocker, consider ACE inhibitor or nitrates
+
*Add ASA and beta blocker, consider ACE inhibitor or nitrates
   
== Preoperative assessment ==
+
==Preoperative assessment==
   
* If surgery is emergent, proceed to OR
+
*If surgery is emergent, proceed to OR
* If not emergent, then rule out ACS and treat this first
+
*If not emergent, then rule out ACS and treat this first
* If not having ACS, then risk stratify with AHA class or RCRI or NSQuIP
+
*If not having ACS, then risk stratify with AHA class or RCRI or NSQuIP
* Elective surgery should be delayed for:
+
*Elective surgery should be delayed for:
** Anticoagulation/antiplatelets
+
**Anticoagulation/antiplatelets
** Electrolyte abnormalities
+
**Electrolyte abnormalities
** Infection, especially pneumonia
+
**Infection, especially pneumonia
** Obstructions in the vasculature (ACS or PE within the past month)
+
**Obstructions in the vasculature (ACS or PE within the past month)
** Unstable vitals
+
**Unstable vitals
   
== Prognosis ==
+
==Prognosis==
   
* 15-25% in-hospital mortality
+
*15-25% in-hospital mortality
* Outcomes are related to peak troponin (per VISION study)
+
*Outcomes are related to peak troponin (per VISION study)
   
 
[[Category:Perioperative medicine]]
 
[[Category:Perioperative medicine]]

Latest revision as of 08:19, 2 August 2020

Background

Epidemiology

  • Represents 1-6% of cardiac events

Etiology

  • Bleeding (35%)
  • Cardiac cause (44%), including MI, AV block, arrhythmias
  • Other (21%), including PE, anaphylaxis, and hypoxemia

Pathophysiology

  • Thrombosis
  • Catecholamine surges from stress state
  • Obstruction
  • Infection or inflammation
  • Increased demand, from tachycardia, fever, hypotension, anemia, and hypoxemia

Clinical Manifestations

Diagnosis

  • Increased troponin with typical pattern
  • Signs of ischemia, including Q waves on ECG or wall motion abnormalities on echocardiography

Management

  • Treat underlying cause
  • Add ASA and beta blocker, consider ACE inhibitor or nitrates

Preoperative assessment

  • If surgery is emergent, proceed to OR
  • If not emergent, then rule out ACS and treat this first
  • If not having ACS, then risk stratify with AHA class or RCRI or NSQuIP
  • Elective surgery should be delayed for:
    • Anticoagulation/antiplatelets
    • Electrolyte abnormalities
    • Infection, especially pneumonia
    • Obstructions in the vasculature (ACS or PE within the past month)
    • Unstable vitals

Prognosis

  • 15-25% in-hospital mortality
  • Outcomes are related to peak troponin (per VISION study)